GILEAD SCIENCES, INC. — 13F Holdings & Portfolio
CIK 882095 · latest 13F-HR filed 2026-05-08
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$2.12B
Long-equity book
6
Distinct positions
2026-03-31
Filed 2026-05-08
+0 / −0 / ↑1 / ↓5
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Trims
- Arcus Biosciences Inc-$70.1M -9.4%
- Galapagos NV-$49.4M -9.0%
- Assembly Biosciences Inc-$28.2M -18.4%
- Kyverna Therapeutics Inc-$3.2M -8.2%
- Xilio Therapeutics Inc-$359.5K -6.2%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Arcellx Inc | ACLX | 03940C100 | $771.7M | 36.44% | 6,720,803 | SH |
| 2 | Arcus Biosciences Inc | RCUS | 03969F109 | $678.8M | 32.05% | 31,424,760 | SH |
| 3 | Galapagos NV | GLPG | 36315X101 | $501.2M | 23.67% | 16,707,477 | SH |
| 4 | Assembly Biosciences Inc | ASMB | 045396207 | $125.0M | 5.90% | 4,505,391 | SH |
| 5 | Kyverna Therapeutics Inc | KYTX | 501976104 | $35.6M | 1.68% | 4,126,119 | SH |
| 6 | Xilio Therapeutics Inc | XLO | 98422T100 | $5.5M | 0.26% | 650,389 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-08 | $2.12B | 6 | 0001123292-26-000642 |
| 2025-12-31 | 2026-02-12 | $1.94B | 6 | 0001123292-26-000164 |